UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

URGN

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-22Shares Purchased (TTM):0Shares Sold (TTM):54,668

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:44,577,121Shares Outstanding:50,182,758Institutional Ownership Pct.:88.83%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Cash And Cash Equivalents At Carrying Value	79	110	111	90	93	104	172	125	220	131	95	119
Available For Sale Securities Debt Securities Curr…	29	30	10	37	64	92	65	125	21	33	42	28
Assets Current
Assets Current	235	237	186	169	197	237	276	295	279	197	169	182
Restricted Cash Current	1	1	1	1	1	1	1	1	1	1	1	1
Accounts Receivable Net Current	89	55	33	20	20	20	20	23	17	14	15	13
Inventory Net	25	21	16	8	7	8	9	8	7	7	6	5
Prepaid Expense And Other Assets Current	13	20	15	12	12	13	9	14	12	10	10	16
Assets Noncurrent
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Restricted Investments Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	-	-	-	-	-	-	-	1	1	1	2	2
Available For Sale Securities Debt Securities Nonc…	-	-	0	0	5	5	5	5	0	0	5	7
Other Assets Noncurrent	9	7	5	7	1	0	1	0	1	1	2	2
Assets	253	254	200	185	209	248	286	302	282	201	178	194
Accounts Payable And Accrued Liabilities Current	40	35	28	26	31	30	27	20	24	18	17	14
Liabilities Current
Liabilities Current	62	51	46	42	48	42	46	33	34	26	31	26
Employee Related Liabilities Current	12	10	14	11	12	7	11	9	7	5	11	8
Other Liabilities Current	8	5	5	5	5	5	8	4	4	3	4	4
Long Term Debt Noncurrent	189	190	122	122	123	122	122	122	98	98	99	99
Liabilities Noncurrent
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	0	0	1	1	1
Liability For Uncertain Tax Positions Noncurrent	4	4	4	4	4	4	4	3	3	3	3	3
Liabilities	385	378	306	300	302	294	295	276	252	241	244	236
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	865	859	854	818	806	803	797	794	775	671	614	611
Stockholders Equity
Stockholders Equity	-132	-124	-105	-115	-93	-46	-9	26	30	-40	-65	-42
Retained Earnings Accumulated Deficit	-998	-983	-960	-933	-900	-850	-806	-769	-745	-712	-679	-653
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	0	0	-0	-0	0	-0
Liabilities And Stockholders Equity	253	254	200	185	209	248	286	302	282	201	178	194
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	49	49	48	47	46	46	42	42	41	36	32	31
Shares Outstanding	49	49	48	47	46	46	42	42	41	36	32	42

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	7.16%	31.58%	56.08%	-	-	-	-	-	-	-	-	-
2025	-33.84%	21.90%	74.15%	4.63%	-1.34%	2.04%	22.39%	-2.17%	-15.04%	-9.73%	26.76%	51.89%
2024	1.07%	21.50%	19.97%	-11.56%	-15.11%	-18.45%	3.76%	-12.09%	-16.34%	3.33%	16.03%	-57.26%
2023	-	-	-	-14.47%	-33.95%	-47.85%	22.17%	18.24%	41.01%	-5.09%	-0.21%	-7.19%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.80	4.69	4.01	3.99	4.14	5.65	6.01	9.00	8.15	7.47	5.42	7.06
Quick Ratio	3.20	3.89	3.34	3.51	3.74	5.16	5.62	8.34	7.58	6.80	4.91	6.25
Working Capital	173.51M	186.83M	139.61M	126.30M	149.32M	195.18M	230.19M	262.31M	244.75M	170.42M	137.97M	156.34M
Leverage & Debt
Debt to Equity	-2.91	-3.04	-2.90	-2.60	-3.24	-6.33	-33.46	10.83	8.30	-6.00	-3.73	-5.61
Interest Coverage TTM	-4.11	-7.00	-8.14	-8.63	-8.34	-7.63	-7.73	-6.85	-5.99	-5.09	-4.45	-4.96
Debt Ratio	1.52	1.49	1.53	1.62	1.45	1.19	1.03	0.92	0.89	1.20	1.37	1.22
Efficiency & Turnover
Asset Turnover TTM	0.82	0.56	0.45	0.40	0.38	0.41	0.39	0.36	0.45	0.54	0.53	0.48
Days Sales Outstanding TTM	104.83	97.49	88.74	80.37	71.78	67.14	72.16	72.80	70.67	57.70	62.10	52.61
Receivables Turnover TTM	3.48	3.74	4.11	4.54	5.09	5.44	5.06	5.01	5.16	6.33	5.88	6.94
Per Share Metrics
Free Cash Flow Per Share TTM	-3.09	-3.31	-3.38	-2.00	-1.71	-2.26	-2.26	-2.06	-2.12	-2.23	-2.66	-2.64
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	90.85%	89.85%	88.66%	87.95%	88.54%	89.68%	90.18%	90.27%	89.87%	89.53%	88.68%	87.92%
Operating Profit Margin TTM	-35.32%	-77.02%	-113.73%	-138.22%	-131.12%	-117.51%	-107.06%	-93.70%	-93.74%	-82.12%	-79.23%	-92.15%
Net Profit Margin TTM	-51.73%	-94.83%	-139.81%	-170.59%	-164.44%	-150.68%	-140.35%	-129.11%	-133.61%	-123.74%	-123.61%	-136.00%
Growth Metrics
Net Revenue Growth (1Y)	100.27%	52.92%	21.45%	8.00%	10.85%	8.98%	9.29%	15.64%	17.22%	24.00%	28.52%	23.76%
Net Income Growth (1Y)	-37.00%	-3.76%	20.98%	42.70%	36.43%	32.70%	24.09%	9.78%	4.16%	-6.53%	-6.87%	-3.90%
EPS Growth (1Y)	-40.30%	-9.06%	7.81%	38.90%	15.75%	3.70%	-16.55%	-24.20%	-39.66%	-41.28%	-26.34%	-32.17%
Valuation Metrics
P/E TTM	-18.99	-6.77	-7.34	-5.82	-4.22	-3.79	-3.60	-5.15	-5.98	-5.33	-4.23	-4.31
P/B TTM	-14.00	-7.26	-10.68	-8.31	-7.00	-11.29	-51.87	23.28	22.42	-13.85	-6.63	-10.78
P/S TTM	9.82	6.42	10.26	9.93	6.94	5.71	5.05	6.65	7.99	6.59	5.23	5.86
Market Cap	1.85B	902.29M	1.13B	958.74M	654.04M	524.49M	456.64M	594.10M	679.61M	555.89M	432.51M	452.50M
Enterprise Value	1.96B	981.85M	1.14B	990.82M	683.64M	542.56M	406.38M	590.89M	557.45M	522.04M	436.06M	431.71M
Calculated Values
Free Cash Flow TTM	-155.83M	-166.04M	-162.73M	-96.06M	-81.46M	-107.39M	-97.06M	-96.38M	-86.02M	-82.48M	-76.57M	-85.28M
Net Debt	109.60M	79.56M	11.47M	32.07M	29.60M	18.08M	-50.25M	-3.21M	-122.16M	-33.85M	3.55M	-20.79M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Schoenberg, Mark

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $35.01

Value: $350,100.00

Shares Owned: 129,763

Relationship: Officer

Ownership: Direct

2026-06-08Sale

Owner: Schoenberg, Mark

Title: Chief Medical Officer

Shares: 5,222

Price/Share: $27.30

Value: $142,560.60

Shares Owned: 139,763

Relationship: Officer

Ownership: Direct

2026-05-08Sale

Owner: Schoenberg, Mark

Title: Chief Medical Officer

Shares: 10,000

Price/Share: $30.00

Value: $300,000.00

Shares Owned: 134,985

Relationship: Officer

Ownership: Direct

2026-02-03Sale

Owner: Smith, Jason Drew

Title: General Counsel

Shares: 7,479

Price/Share: $19.69

Value: $147,261.51

Shares Owned: 51,326

Relationship: Officer

Ownership: Direct

2026-02-03Sale

Owner: Schoenberg, Mark

Title: Chief Medical Officer

Shares: 7,373

Price/Share: $19.69

Value: $145,174.37

Shares Owned: 144,985

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	35.01	$350,100.00	129,763	4
2026-06-08	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	5,222	27.30	$142,560.60	139,763	4
2026-05-08	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	30.00	$300,000.00	134,985	4
2026-02-03	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	7,479	19.69	$147,261.51	51,326	4
2026-02-03	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	7,373	19.69	$145,174.37	144,985	4
2025-11-19	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	25.00	$250,000.00	139,025	4
2025-10-08	Degnan, Chris	Officer	Chief Financial Officer	Direct	Sale	2,203	16.85	$37,120.55	2,280	4
2025-09-08	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	871	19.11	$16,644.81	149,025	4
2025-09-08	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	1,520	19.11	$29,047.20	43,305	4
2025-08-11	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	10,000	17.69	$176,900.00	148,229	4
2025-07-28	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	5,149	19.14	$98,551.86	158,229	4
2025-07-28	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	7,522	19.14	$143,971.08	41,492	4
2025-06-09	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	5,162	7.37	$38,043.94	153,378	4
2025-01-31	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	7,379	11.14	$82,202.06	26,468	4
2025-01-31	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	4,551	11.14	$50,698.14	145,666	4
2024-09-09	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	859	13.08	$11,235.72	145,091	4
2024-09-09	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	1,521	13.08	$19,894.68	25,226	4
2024-06-10	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	5,153	13.08	$67,401.24	144,284	4
2024-03-18	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	12,000	14.05	$168,600.00	139,437	4
2024-02-01	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	4,993	15.78	$78,789.54	18,824	4/A
2024-02-01	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	3,789	15.78	$59,790.42	149,423	4/A
2024-01-31	Schoenberg, Mark	Officer	Chief Medical Officer	Direct	Sale	3,789	15.74	$59,638.86	149,423	4
2024-01-31	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	4,993	15.74	$78,589.82	18,824	4
2023-08-31	Smith, Jason Drew	Officer	General Counsel	Direct	Sale	3,800	18.01	$68,438.00	18,407	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

88.83%

Inst. Shares: 44,577,121

Shares Outstanding: 50,182,758

2025-12-31

84.52%

Inst. Shares: 40,665,674

Shares Outstanding: 48,116,098

2025-09-30

86.02%

Inst. Shares: 41,341,000

Shares Outstanding: 48,057,386

2025-06-30

77.19%

Inst. Shares: 36,850,676

Shares Outstanding: 47,739,816

2025-03-31

83.94%

Inst. Shares: 39,807,202

Shares Outstanding: 47,422,119

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	44,577,121	50,182,758	88.83%
2025-12-31	40,665,674	48,116,098	84.52%
2025-09-30	41,341,000	48,057,386	86.02%
2025-06-30	36,850,676	47,739,816	77.19%
2025-03-31	39,807,202	47,422,119	83.94%
2024-12-31	34,508,102	42,876,737	80.48%
2024-09-30	33,725,917	46,779,637	72.10%
2024-06-30	36,930,154	40,501,315	91.18%
2024-03-31	25,356,682	37,059,186	68.42%
2023-12-31	19,603,474	28,834,303	67.99%
2023-09-30	15,670,387	32,298,182	48.52%
2023-06-30	10,706,332	23,462,016	45.63%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

UroGen Pharma Ltd. (URGN) — SEC Financial Statements & Analysis

UroGen Pharma Ltd. (URGN) is a pharmaceutical preparations company, incorporated in L3. UroGen Pharma Ltd. trades on Nasdaq as: URGN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), UroGen Pharma Ltd. reported a 100.27% year-over-year revenue growth, a Gross Profit Margin of 90.85% (TTM), a Debt-to-Equity ratio of -2.91x, a Price-to-Sales (P/S) ratio of 9.82x (TTM), a Price-to-Book (P/B) ratio of -14.00x (TTM), at a market cap of $1.85B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 100.27%
Gross Profit Margin TTM: 90.85%
Debt To Equity: -2.91x
P/S TTM: 9.82x
P/B TTM: -14.00x
Market Cap: $1.85B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is UroGen Pharma Ltd. in?

UroGen Pharma Ltd. (URGN) operates in the Pharmaceutical Preparations industry.

What is URGN's market cap?

UroGen Pharma Ltd. (URGN) has a market capitalization of $1.85B as of 2026-06-30.

What exchange does URGN trade on?

UroGen Pharma Ltd. (URGN) trades on the Nasdaq.

Where is UroGen Pharma Ltd. incorporated?

UroGen Pharma Ltd. is incorporated in Israel.